Continuing Education Activity

Granuloma faciale comprises a rare, benign inflammatory skin disorder that typically presents as isolated, well-defined reddish-brown to violaceous papules, nodules, or plaques. Lesions often exhibit follicular accentuation and telangiectasia and are generally asymptomatic. Granuloma faciale is most commonly seen in middle-aged white men, but reported cases span the 2nd to 7th decades of life. Pediatric presentations have also been described.

Most lesions appear singly on the face, particularly on the forehead, nose, or cheeks. However, multiple lesions may occur, including in extrafacial locations such as the scalp, trunk, nasal cavity, or extremities. While most patients remain asymptomatic, occasional pruritus or burning has been described. The clinical course tends to be chronic and relapsing, and spontaneous resolution is uncommon. Involvement of cosmetically sensitive areas contributes to a significant psychosocial burden.

Diagnosis is often delayed or mistaken for other dermatoses, including sarcoidosis, lupus erythematosus, or pseudolymphoma. Histopathologic evaluation is critical for confirmation and typically reveals a dense polymorphous dermal infiltrate with a Grenz zone. Although granuloma faciale is benign, treatment can be difficult. Lesions often respond inconsistently to therapy and frequently recur following discontinuation.

This activity for healthcare professionals is designed to enhance learners' competence in evaluating and managing granuloma faciale. Participants will deepen their understanding of the condition's etiology, epidemiology, genetics, and clinical presentation. Current diagnostic and therapeutic recommendations will be emphasized. Greater proficiency will equip clinicians to collaborate effectively within interprofessional teams caring for affected individuals.

Objectives:

• Identify the clinical and diagnostic features suggestive of granuloma faciale.
• Implement individualized, evidence-based strategies for managing granuloma faciale and mitigating its potential complications.
• Improve patient understanding of granuloma faciale by emphasizing its course, treatment options, and the value of consistent care in achieving the best outcomes.
• Apply effective strategies to enhance care coordination among interprofessional team members, facilitating positive outcomes for patients with granuloma faciale.

Introduction

Granuloma faciale is a rare, benign inflammatory skin disease that usually presents as isolated, well-defined reddish-brown to violaceous asymptomatic papules, nodules, or plaques with follicular accentuation and telangiectasia. This skin disorder was first described as “eosinophilic granuloma” in 1945 by Wigley JE.[1] Granuloma faciale typically affects middle-aged white men but has been reported in individuals ranging from the 2nd to the 7th decade of life. Childhood cases have also been documented.[2][3][4] The condition typically presents as a single lesion on the face, but multiple lesions or extrafacial involvement may also occur.[5] Extrafacial localizations include the scalp, trunk, nasal cavity, or extremities. Facial lesions most frequently appear on the forehead, nose, or cheeks.[6]

Etiology

The etiology of granuloma faciale is unknown. However, the condition's predilection for sun-exposed areas suggests a possible association with actinic damage. Other proposed contributing factors include allergic hypersensitivity, trauma, and, less commonly, radiation therapy.[7][8]

Epidemiology

Granuloma faciale is a relatively rare condition that primarily affects adults of both sexes, with a slight male predominance. Although all races may be affected, granuloma faciale most commonly occurs in white individuals. The mean age of onset is approximately 52 years.[9][10]

Pathophysiology

The pathogenesis of granuloma faciale is not well-established. Some authors consider this skin disorder a variant of chronic cutaneous vasculitis, possibly resulting from a localized Arthus phenomenon.[11]

Histopathology

Specific histopathologic features have not been clearly defined for granuloma faciale. The most frequently reported findings include a Grenz zone, dermal infiltration of neutrophils, and telangiectasia. Inflammatory infiltrates in the dermis are typically separated from the overlying epidermis by a narrow Grenz zone of uninvolved dermis. Dilated follicular ostia and follicular plugs are commonly observed. The dermal infiltrates are predominantly perivascular and composed mainly of neutrophils, lymphocytes, and plasma cells, with frequent eosinophil involvement.

Vascular alterations are common and consist primarily of perivascular infiltrates that may extend into vessel walls and produce leukocytoclasia. Necrotizing vasculitis is rarely observed. The presence of hemosiderin and red blood cell extravasation supports underlying vascular injury.

Direct immunofluorescence is not uniformly positive and lacks pathognomonic specificity for granuloma faciale. When present, findings include granular perivascular or basement membrane zone deposits of immunoglobulin G, with less intense deposits of immunoglobulin M, and, occasionally, immunoglobulin A, and complement components 3 and 1q.

History and Physical

Granuloma faciale typically presents as a chronic, progressive, asymptomatic, isolated, well-defined reddish-brown to violaceous papule, nodule, or plaque with follicular accentuation and telangiectasia. The most commonly affected sites are the face and other sun-exposed areas. Dermoscopy serves as a valuable tool in clinical evaluation and often mirrors both the clinical and histologic features of granuloma faciale. The most frequently observed dermoscopic findings include linear arborizing vessels, dilated follicular openings, and brown dots or globules. These brown structures are thought to correspond to hemosiderin deposition.[12][13]

Evaluation

Granuloma faciale follows a progressive, chronic course characterized by recurrent acute exacerbations rather than distinct acute and chronic phases. Consequently, histopathologic findings often reflect overlapping features of both acute and chronic inflammation, making it difficult to assess chronicity based solely on tissue examination. Laboratory evaluation is generally unremarkable, although mild peripheral eosinophilia may be observed. While granuloma faciale is a benign condition, spontaneous resolution is uncommon, and most cases require therapeutic intervention. Currently available treatments carry a significant risk of recurrence.[14][15]

Treatment / Management

Topical Treatments

Topical therapies are considered the 1st-line treatment for granuloma faciale, with calcineurin inhibitors, particularly tacrolimus, being the most frequently used agents. Calcineurin inhibitors reduce T-cell activation and downregulate interleukin 2 expression. Tacrolimus 0.1% ointment, applied twice daily, appears to be the most effective initial option.[16][17][18][19][20] However, lesion clearance may require prolonged therapy, with most cases responding within 2 to 6 months of continuous treatment.[21][22][23][24]

Topical or intralesional corticosteroids have also demonstrated variable effectiveness in treating granuloma faciale. Intralesional corticosteroids may be combined with cryotherapy for enhanced results. The most commonly reported regimen involves triamcinolone acetonide at concentrations of 5 to 20 mg/mL, administered weekly or monthly.[25][26][27][28][29]

Additional treatment approaches have included topical dapsone 5% gel, which has shown favorable outcomes in isolated case reports.[30] Intralesional rituximab at a dose of 10 mg/mL once monthly has been used in 3 reported cases, with relatively good responses.[31][32] More recently, adjunct therapy with topical Janus kinase inhibitors, such as ruxolitinib, has been explored for refractory cases, with promising results in emerging case studies.[33][34]

Systemic Therapies

Systemic treatments have been employed in the management of granuloma faciale, particularly in refractory or widespread cases. Dapsone, administered at doses ranging from 50 to 150 mg per day, has demonstrated clinical effectiveness.[35][36][37] Although the exact mechanism of action remains unclear, dapsone is known to exert anti-inflammatory, antimicrobial, and antiprotozoal effects. The drug's anti-inflammatory properties may involve multiple mechanisms, including inhibition of prostaglandin synthesis and production, as well as prevention of neutrophil extravasation at the lesional site.[38][39]

Systemic corticosteroids have also been used, though responses are typically partial and inconsistent.[40][41] Clofazimine, an anti-leprosy agent with anti-inflammatory and anti-proliferative effects on lymphocytes and carcinoma cells, has received limited attention in the treatment of granuloma faciale. A dose of 300 mg per day has shown favorable outcomes in a few cases after 3 to 5 months of treatment.[42][43]

Surgery and Other Procedures

Several procedural and surgical therapies have been explored for the treatment of granuloma faciale, particularly in cases resistant to topical or systemic agents. Cryotherapy using liquid nitrogen has been reported as an effective standalone option.[44]

Laser therapy has also been widely discussed in the literature, with outcomes varying based on lesion characteristics, laser type, and operator experience. The pulsed dye laser targets oxyhemoglobin within blood vessels and has demonstrated favorable cosmetic outcomes, particularly for superficial lesions. Multiple treatment sessions are often required, typically spaced 2 to 4 months apart. Compared to other laser modalities, the pulsed dye laser is associated with a lower risk of scarring, although pain during the procedure and posttreatment bruising are common side effects.[45][46][47]

Other lasers used in the treatment of granuloma faciale include the potassium-titanyl-phosphate 532-nm laser, which has shown good results following 5 to 10 days of daily treatment without significant scarring. The carbon dioxide laser has also been employed in select cases.[48][49][50][51] The argon laser, operating at 480 to 520 nm, offers more selective targeting of oxyhemoglobin than the carbon dioxide laser but may result in greater nonspecific tissue injury due to wider heat diffusion.[52][53]

Additional therapies include phototherapy, particularly topical psoralen combined with ultraviolet A, and surgical approaches such as excision with or without grafting. Dermabrasion has also been reported as a treatment option.[54][55]

Differential Diagnosis

Several cutaneous conditions can mimic the clinical presentation of granuloma faciale. The differential diagnosis includes sarcoidosis, discoid lupus erythematosus, rosacea, mycobacterial infections, deep fungal infections of the skin, cutaneous lymphoma, and basal cell carcinoma.[56]

Erythema elevatum diutinum (EED) is a key histopathologic differential diagnosis, as both conditions may display overlapping features such as fibrosing vasculitis.[57] A common pathogenic mechanism has been proposed for both EED and granuloma faciale. The primary distinction is clinical. EED typically presents as multiple lesions on extensor surfaces, whereas granuloma faciale usually manifests as a solitary lesion on the face. Diagnostic difficulty arises when EED presents on the face or when granuloma faciale involves extrafacial sites. A dense eosinophilic infiltrate strongly supports a diagnosis of granuloma faciale, while granulomatous nodules may be observed in EED.

Additionally, EED is often associated with underlying systemic conditions, including hematologic disorders, autoimmune diseases, HIV infection, other infections, and insect bites. In contrast, granuloma faciale is rarely linked to systemic disease.[58]

Prognosis

Granuloma faciale follows a benign but persistent course, with spontaneous resolution occurring in fewer than 10% of cases. Lesions often persist for years to decades, and treatment is frequently necessary to control progression or achieve remission. Recurrence rates are high, reported in 50% to 60% of cases, particularly following the cessation of therapy with superficial modalities such as topical corticosteroids or cryotherapy.

Although the condition is primarily localized to the face, extrafacial lesions occur in approximately 10% to 15% of cases, most often on sun-exposed areas such as the scalp, trunk, or extremities. Granuloma faciale carries no risk of systemic involvement or malignant transformation and shows no association with systemic vasculitis or autoimmune disease.

Newer therapeutic approaches, including topical calcineurin inhibitors such as tacrolimus, pulsed dye laser, and intralesional corticosteroids, have shown success in inducing remission, with some reports documenting partial or complete clearance in up to 70% of treated patients. The long-term prognosis is favorable with respect to morbidity, although the cosmetic burden and refractory nature in some cases require ongoing management and patient counseling.

Complications

Granuloma faciale, though histopathologically suggestive of leukocytoclastic vasculitis, is confined to the dermis and lacks systemic vasculitic involvement. Complications are therefore primarily local and cosmetic rather than systemic. The most significant complication is persistent disfigurement, particularly when lesions are nodular, hypertrophic, or located in cosmetically sensitive areas such as the nasal dorsum, cheeks, or forehead.

Chronic lesions may develop telangiectasia, postinflammatory hyperpigmentation, atrophy, or scarring, especially after repeated interventions including intralesional corticosteroids, cryotherapy, or ablative laser procedures. Aggressive treatment in recalcitrant cases may lead to cutaneous thinning or hypopigmentation, which can contribute to psychological distress and reduced quality of life. Secondary bacterial infection is uncommon but may occur in ulcerated or excoriated lesions.

Granuloma faciale does not involve internal organs, progress to systemic vasculitis, or undergo malignant transformation—features that distinguish it from other vasculitic or granulomatous dermatoses. However, the refractory course, with frequent relapse despite treatment, often necessitates long-term dermatologic follow-up and interprofessional collaboration, particularly in patients with extensive or cosmetically deforming disease. Early recognition and careful selection of therapy can help prevent permanent sequelae.

Deterrence and Patient Education

Deterrence of granuloma faciale is limited, as no definitive environmental, infectious, or genetic trigger has been linked to its pathogenesis. Nonetheless, patient education plays a central role in long-term management. Patients should understand that granuloma faciale is a benign, chronic cutaneous condition, typically localized to the face, and carries no risk of systemic involvement or malignant transformation. Although asymptomatic in most cases, lesions may persist for years and often require repeated intervention due to a high rate of recurrence following treatment.

Education should emphasize the importance of adherence to prescribed therapies, including topical agents, laser treatments, and intralesional injections, as well as the need for regular follow-up to assess response and minimize long-term disfigurement. Patients must be cautioned against self-manipulation and unsupervised use of topical corticosteroids, which may exacerbate telangiectasia or lead to atrophy. Psychological support may be appropriate in individuals experiencing distress related to the cosmetic burden, particularly in cases involving facial or treatment-resistant lesions. Camouflage techniques may also be offered as an adjunct to medical therapy. Given the refractory nature of the disease, setting realistic expectations about treatment outcomes and the potential for relapse is critical to maintaining patient engagement and therapeutic success.

Enhancing Healthcare Team Outcomes

Primary care providers and nurse practitioners who encounter persistent facial lesions should refer patients to a dermatologist for comprehensive evaluation. Collaboration with a dermatopathologist is essential to ensure diagnostic accuracy, given the broad range of clinical and histologic differentials associated with granuloma faciale. An interprofessional team that includes physicians, nurse practitioners, physician assistants, and pharmacists provides the best framework for effective case management and coordinated patient care. Surgical treatment, particularly for facial lesions, should be planned in consultation with a plastic surgeon to optimize functional and cosmetic outcomes.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Wigley JE. Eosinophilic Granuloma. ? Sarcoid of Boeck. Proc R Soc Med. 1945 Jan;38(3):125-6. [PMC free article: PMC2181658] [PubMed: 19992999]

2.

Oliveira CC, Ianhez PE, Marques SA, Marques ME. Granuloma faciale: clinical, morphological and immunohistochemical aspects in a series of 10 patients. An Bras Dermatol. 2016 Nov-Dec;91(6):803-807. [PMC free article: PMC5193193] [PubMed: 28099604]

3.

Ortonne N, Wechsler J, Bagot M, Grosshans E, Cribier B. Granuloma faciale: a clinicopathologic study of 66 patients. J Am Acad Dermatol. 2005 Dec;53(6):1002-9. [PubMed: 16310061]

4.

Deen J, Moloney TP, Muir J. Extrafacial Granuloma Faciale: A Case Report and Brief Review. Case Rep Dermatol. 2017 May-Aug;9(2):79-85. [PMC free article: PMC5567072] [PubMed: 28868005]

5.

Ma S, Liu H, Zhang F. Diffuse granuloma faciale. Int J Dermatol. 2023 Jul;62(7):969-970. [PubMed: 36529934]

6.

Lindhaus C, Elsner P. Granuloma Faciale Treatment: A Systematic Review. Acta Derm Venereol. 2018 Jan 12;98(1):14-18. [PubMed: 28880343]

7.

Nigar E, Dhillon R, Carr E, Matin RN. Eosinophilic angiocentric fibrosis and extrafacial granuloma faciale. Histopathology. 2007 Nov;51(5):729-31. [PubMed: 17927606]

8.

Goldner R, Sina B. Granuloma faciale: the role of dapsone and prior irradiation on the cause of the disease. Cutis. 1984 May;33(5):478-9, 482. [PubMed: 6478871]

9.

Marcoval J, Moreno A, Peyr J. Granuloma faciale: a clinicopathological study of 11 cases. J Am Acad Dermatol. 2004 Aug;51(2):269-73. [PubMed: 15280847]

10.

Radin DA, Mehregan DR. Granuloma faciale: distribution of the lesions and review of the literature. Cutis. 2003 Sep;72(3):213-9; quiz 208. [PubMed: 14533833]

11.

Barnadas MA, Curell R, Alomar A. Direct immunofluorescence in granuloma faciale: a case report and review of literature. J Cutan Pathol. 2006 Jul;33(7):508-11. [PubMed: 16872475]

12.

Lallas A, Sidiropoulos T, Lefaki I, Tzellos T, Sotiriou E, Apalla Z. Photoletter to the editor: Dermoscopy of granuloma faciale. J Dermatol Case Rep. 2012 Jun 30;6(2):59-60. [PMC free article: PMC3399680] [PubMed: 22826723]

13.

Chauhan P, Meena D. Dermoscopy of Granuloma Faciale in the Skin of Color. Indian Dermatol Online J. 2022 Sep-Oct;13(5):686-687. [PMC free article: PMC9595152] [PubMed: 36304640]

14.

Ludwig E, Allam JP, Bieber T, Novak N. New treatment modalities for granuloma faciale. Br J Dermatol. 2003 Sep;149(3):634-7. [PubMed: 14511001]

15.

Tomson N, Sterling JC, Salvary I. Granuloma faciale treated successfully with topical tacrolimus. Clin Exp Dermatol. 2009 Apr;34(3):424-5. [PubMed: 19175788]

16.

Lima RS, Maquiné GÁ, Silva Junior RC, Schettini AP, Santos M. Granuloma faciale: a good therapeutic response with the use of topical tacrolimus. An Bras Dermatol. 2015 Sep-Oct;90(5):735-7. [PMC free article: PMC4631240] [PubMed: 26560220]

17.

Cecchi R, Pavesi M, Bartoli L, Brunetti L. Topical tacrolimus in the treatment of granuloma faciale. Int J Dermatol. 2010 Dec;49(12):1463-5. [PubMed: 21091691]

18.

Pérez-Robayna N, Rodríguez-García C, González-Hernández S, Sánchez R, Guimerá F, Sáez M. Successful response to topical tacrolimus for a granuloma faciale in an elderly patient. Dermatology. 2009;219(4):359-60. [PubMed: 19797891]

19.

Mitchell D. Successful treatment of granuloma faciale with tacrolimus. Dermatol Online J. 2004 Oct 15;10(2):23. [PubMed: 15530313]

20.

Eetam I, Ertekin B, Unal I, Alper S. Granuloma faciale: Is it a new indication for pimecrolimus? A case report. J Dermatolog Treat. 2006;17(4):238-40. [PubMed: 16971320]

21.

Marcoval J, Moreno A, Bordas X, Peyrí J. Granuloma faciale: treatment with topical tacrolimus. J Am Acad Dermatol. 2006 Nov;55(5 Suppl):S110-1. [PubMed: 17052523]

22.

Jedlicková H, Feit J, Semrádová V. Granuloma faciale successfully treated with topical tacrolimus: a case report. Acta Dermatovenerol Alp Pannonica Adriat. 2008 Mar;17(1):34-6. [PubMed: 18454269]

23.

Patterson C, Coutts I. Granuloma faciale successfully treated with topical tacrolimus. Australas J Dermatol. 2009 Aug;50(3):217-9. [PubMed: 19659988]

24.

Dourmishev L, Ouzounova-Raykova V, Broshtilova V, Miteva L. Granuloma faciale effectively treated with topical pimecrolimus. Acta Dermatovenerol Croat. 2014;22(4):305-7. [PubMed: 25580794]

25.

Dowlati B, Firooz A, Dowlati Y. Granuloma faciale: successful treatment of nine cases with a combination of cryotherapy and intralesional corticosteroid injection. Int J Dermatol. 1997 Jul;36(7):548-51. [PubMed: 9268759]

26.

Zargari O. Disseminated granuloma faciale. Int J Dermatol. 2004 Mar;43(3):210-2. [PubMed: 15009395]

27.

Verma R, Das AL, Vaishampayan SS, Vaidya S. Keloidal granuloma faciale with extrafacial lesions. Indian J Dermatol Venereol Leprol. 2005 Sep-Oct;71(5):345-7. [PubMed: 16394461]

28.

Mashood AA., Simeen-ber-Rahman. Granuloma faciale -- an unusual presentation. J Coll Physicians Surg Pak. 2006 Apr;16(4):296-7. [PubMed: 16624198]

29.

De D, Kanwar AJ, Radotra BD, Gupta S. Extrafacial granuloma faciale: report of a case. J Eur Acad Dermatol Venereol. 2007 Oct;21(9):1284-6. [PubMed: 17894740]

30.

Babalola O, Zhang J, Kristjansson A, Whitaker-Worth D, McCusker M. Granuloma faciale treated with topical dapsone: a case report. Dermatol Online J. 2014 Aug 17;20(8) [PubMed: 25148282]

31.

Morgado-Carrasco D, Giavedoni P, Mascaró JM, Iranzo P. Assessment of Treatment of Refractory Granuloma Faciale With Intralesional Rituximab. JAMA Dermatol. 2018 Nov 01;154(11):1312-1315. [PMC free article: PMC6248127] [PubMed: 30193300]

32.

Joly E, Duval-Modeste A, Sabatier R, Arhant G, Cellier L, Mouthon M, Comoz F, Joly P, Dompmartin A. Intralesional rituximab treatment for atypical refractory granuloma faciale. Ann Dermatol Venereol. 2021 Dec;148(4):272-274. [PubMed: 34456047]

33.

Chen A, Harview CL, Rand SE, Harms JL. Refractory granuloma faciale successfully treated with adjunct topical JAK inhibitor. JAAD Case Rep. 2023 Mar;33:91-94. [PMC free article: PMC9989295] [PubMed: 36895509]

34.

Wong A, Stahly S, Kieffer J, Dunn C, Nathoo R. Topical ruxolitinib for the treatment of granuloma faciale. JAAD Case Rep. 2023 Jun;36:73-74. [PMC free article: PMC10220211] [PubMed: 37250006]

35.

Holme SA, Laidler P, Holt PJ. Concurrent granuloma faciale and eosinophilic angiocentric fibrosis. Br J Dermatol. 2005 Oct;153(4):851-3. [PubMed: 16181479]

36.

Gupta L, Naik H, Kumar NM, Kar HK. Granuloma faciale with extrafacial involvement and response to tacrolimus. J Cutan Aesthet Surg. 2012 Apr;5(2):150-2. [PMC free article: PMC3461795] [PubMed: 23060713]

37.

Fumo G, Patta F, Milo C, Pilloni L, Atzori L. A nose for trouble. Diagnosis: Granuloma faciale. Indian J Dermatol Venereol Leprol. 2015 Jan-Feb;81(1):93-4. [PubMed: 25566920]

38.

Zampeli E, Moutsopoulos HM. Dapsone: an old drug effective for subacute cutaneous lupus erythematosus. Rheumatology (Oxford). 2019 May 01;58(5):920-921. [PubMed: 30615176]

39.

Pfeiffer C, Wozel G. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2003 Feb;48(2):308-9. [PubMed: 12582416]

40.

Yuan C, Bu W, Chen X, Gu H. A case of granuloma faciale successfully treated with oral prednisone, tranilast and thalidomide. Postepy Dermatol Alergol. 2018 Feb;35(1):109-112. [PMC free article: PMC5872251] [PubMed: 29599681]

41.

Sand FL, Thomsen SF. Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients. Dermatol Ther. 2015 May-Jun;28(3):158-65. [PubMed: 25731720]

42.

Wollina U, Karte K, Geyer A, Stuhlert A, Bocker T. Clofazimine in inflammatory facial dermatosis--granuloma faciale and lipogranulomatosis subcutanea (Rothmann-Makai). Acta Derm Venereol. 1996 Jan;76(1):77-9. [PubMed: 8721503]

43.

Gómez-de la Fuente E, del Rio R, Rodriguez M, Guerra A, Rodriguez-Peralto JL, Iglesias L. Granuloma faciale mimicking rhinophyma: response to clofazimine. Acta Derm Venereol. 2000 Mar-Apr;80(2):144. [PubMed: 10877139]

44.

Panagiotopoulos A, Anyfantakis V, Rallis E, Chasapi V, Stavropoulos P, Boubouka C, Katsambas A. Assessment of the efficacy of cryosurgery in the treatment of granuloma faciale. Br J Dermatol. 2006 Feb;154(2):357-60. [PubMed: 16433810]

45.

Fikrle T, Pizinger K. Granuloma Faciale treated with 595-nm pulsed dye laser. Dermatol Surg. 2011 Jan;37(1):102-4. [PubMed: 21070474]

46.

Hruza GJ, Ammirati CT. Granuloma faciale treated with 595-nm pulsed dye laser. Dermatol Surg. 2011 Jul;37(7):1060-1. [PubMed: 21711410]

47.

Erceg A, de Jong EM, van de Kerkhof PC, Seyger MM. The efficacy of pulsed dye laser treatment for inflammatory skin diseases: a systematic review. J Am Acad Dermatol. 2013 Oct;69(4):609-615.e8. [PubMed: 23711766]

48.

Chung WK, Park GH, Kim CH, Chang SE, Lee MW, Choi JH, Moon KC, Koh JK. Keloidal granuloma faciale after CO2 laser treatment for melanocytic naevus. J Eur Acad Dermatol Venereol. 2009 May;23(5):611-2. [PubMed: 19415815]

49.

Wheeland RG, Ashley JR, Smith DA, Ellis DL, Wheeland DN. Carbon dioxide laser treatment of granuloma faciale. J Dermatol Surg Oncol. 1984 Sep;10(9):730-3. [PubMed: 6434613]

50.

Prideaux A, Hitchens E, Thomas K, Wainman H, Keith D. A case of resistant granuloma faciale successfully treated with ablative fractional carbon dioxide laser. J Cosmet Laser Ther. 2024 Nov 16;26(5-8):136-137. [PubMed: 39471333]

51.

Bakkour W, Madan V. Rhinophyma-like granuloma faciale successfully treated with carbon dioxide laser. Br J Dermatol. 2014 Feb;170(2):474-5. [PubMed: 24111815]

52.

Apfelberg DB, Druker D, Maser MR, Lash H, Spence B, Deneau D. Granuloma faciale. Treatment with the argon laser. Arch Dermatol. 1983 Jul;119(7):573-6. [PubMed: 6859900]

53.

Cheung ST, Lanigan SW. Granuloma faciale treated with the pulsed-dye laser: a case series. Clin Exp Dermatol. 2005 Jul;30(4):373-5. [PubMed: 15953073]

54.

Hudson LD. Granuloma faciale: treatment with topical psoralen and UVA. J Am Acad Dermatol. 1983 Apr;8(4):559. [PubMed: 6853786]

55.

Bergfeld WF, Scholes HT, Roenigk HH. Granuloma faciale--treatment by dermabrasion. Report of a case. Cleve Clin Q. 1970 Oct;37(4):215-8. [PubMed: 5520807]

56.

Frankel DH, Soltani K, Medenica MM, Rippon JW. Tinea of the face caused by Trichophyton rubrum with histologic changes of granuloma faciale. J Am Acad Dermatol. 1988 Feb;18(2 Pt 2):403-6. [PubMed: 3343409]

57.

Frantz R, Chukwuma O, Sokumbi O, Satcher K, Kallis P, Vincek V, Motaparthi K. Identifying histopathologic features of erythema elevatum diutinum and granuloma faciale. J Cutan Pathol. 2022 Mar;49(3):323-326. [PubMed: 34939211]

58.

Ziemer M, Koehler MJ, Weyers W. Erythema elevatum diutinum - a chronic leukocytoclastic vasculitis microscopically indistinguishable from granuloma faciale? J Cutan Pathol. 2011 Nov;38(11):876-83. [PubMed: 21883365]

Disclosure: Mahdi Al Dhafiri declares no relevant financial relationships with ineligible companies.

Disclosure: Hasnain Syed declares no relevant financial relationships with ineligible companies.

Disclosure: Feroze Kaliyadan declares no relevant financial relationships with ineligible companies.